702POutcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC). (23rd October 2018) - Kelley, R K; El-Khoueiry, A B; Meyer, T; Rimassa, L; Merle, P; Chan, S L; Tran, A; Parnis, F; Tam, V C; Cattan, S; Markby, D W; Clary, D O; et al.